Information services
Slow Ledger 38 organizes legal-status context around ibogaine into guides, comparisons, research summaries, glossary notes, and FAQ collections. The aim is to make distinctions visible: federal scheduling is not the same as authorized research, state action, an FDA pathway, or lawful public access.
What is covered
These are informational offerings, not medical or clinical services. They are built for people seeking careful context on U.S. ibogaine scheduling, research policy, and legal access.
In-depth guides trace the difference between federal scheduling history and later discussions of research or policy. The scheduling timeline keeps those events in sequence without treating a policy discussion as a change in public legality.
Short frameworks separate the questions readers often combine: what federal law says, what authorized research may involve, what a state action does or does not change, and what remains outside lawful public access. Our independent resource approach explains why that separation matters.
Comparisons help readers distinguish U.S. legal context from discussions of care outside the country, including information about European treatment-center options. A comparison is context only; it is not a recommendation, a safety clearance, or a statement of legality.
Research summaries put drug-development and regulatory terms into plain language. The FDA’s drug development and approval process describes a pathway that is separate from public access to an investigational substance.
Plain-language comparison
Federal scheduling, clinical investigation, state-level developments, and treatment marketing can use overlapping language while describing different things. The rescheduling and research process is presented as a distinct policy and regulatory topic, not as proof that ibogaine is available for general lawful use in the United States.
For basic terminology, the overview of ibogaine can provide background on the compound, while official legal classifications should be checked against current government sources and qualified legal guidance.
Reading sequence
Use the information in sequence when encountering claims about ibogaine, access, or policy. Each step narrows what can responsibly be concluded from the available language.
Identify whether the claim concerns federal scheduling, an authorized study, a state action, a regulatory pathway, or a service offered outside the United States.
Check the governing source and date. The DEA’s explanation of drug scheduling helps establish why a federal schedule is a specific legal category rather than a general description of risk or research interest.
Compare claims against the broader context, including the state-by-state legal snapshot, before drawing conclusions about access in any particular location.
Pause when a claim moves from legal description to treatment promise. Information about ibogaine and alcohol addiction or ibogaine and depression should not be read as medical advice, a safety determination, or a substitute for qualified care.
FAQ collections
The FAQ format is intended to clarify common wording, not to create legal or medical conclusions. For a wider orientation to the subject, begin with the ibogaine legal-status overview.
No. A timeline can distinguish historical federal scheduling, research interest, state actions, and FDA pathways, but it does not itself establish lawful public access or medical safety.
No. Listings such as treatment centers near me or affordable ibogaine treatment information may be part of a reader’s search, but they do not settle lawfulness, oversight, suitability, or safety.
Documentary material, including an ibogaine documentary resource, can add narrative context. It should be distinguished from primary legal materials, current regulatory information, and medical evidence.
Slow Ledger 38 provides independent guides, comparisons, glossary context, research summaries, and FAQ collections. It is not a clinic, medical provider, or licensed treatment center.
Start with the record
Review the timeline as a tool for orientation, then consult current primary sources and qualified professionals for decisions involving law, health, or treatment.